These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

351 related items for PubMed ID: 31191704

  • 1. Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout.
    Pérez-Ruiz F, Jansen T, Tausche AK, Juárez-Campo M, Gurunath RK, Richette P.
    Drugs Context; 2019; 8():212581. PubMed ID: 31191704
    [Abstract] [Full Text] [Related]

  • 2. Lesinurad: A Review in Hyperuricaemia of Gout.
    Deeks ED.
    Drugs Aging; 2017 May; 34(5):401-410. PubMed ID: 28425024
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Lesinurad in Patients with Hyperuricemia Associated with Gout: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Wu JY, Chang YT, Lin YC, Lee CH, Loh EW, Wu MY, Chang YS, Tam KW.
    Pharmacotherapy; 2018 Nov; 38(11):1106-1119. PubMed ID: 30246299
    [Abstract] [Full Text] [Related]

  • 4. Comparison of efficacy and safety of urate-lowering therapies for hyperuricemic patients with gout: a meta-analysis of randomized, controlled trials.
    Fan M, Liu J, Zhao B, Wu X, Li X, Gu J, Schlesinger N.
    Clin Rheumatol; 2021 Feb; 40(2):683-692. PubMed ID: 32654080
    [Abstract] [Full Text] [Related]

  • 5. Individualized treatment strategies for hyperuricemia informed by a semi-mechanistic exposure-response model of uric acid dynamics.
    Aksenov S, Peck CC, Eriksson UG, Stanski DR.
    Physiol Rep; 2018 Mar; 6(5):. PubMed ID: 29488355
    [Abstract] [Full Text] [Related]

  • 6. Lesinurad Combined With Allopurinol: A Randomized, Double-Blind, Placebo-Controlled Study in Gout Patients With an Inadequate Response to Standard-of-Care Allopurinol (a US-Based Study).
    Saag KG, Fitz-Patrick D, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, Becker MA.
    Arthritis Rheumatol; 2017 Jan; 69(1):203-212. PubMed ID: 27564409
    [Abstract] [Full Text] [Related]

  • 7. Lesinurad, a Selective URAT-1 Inhibitor With a Novel Mechanism in Combination With a Xanthine Oxidase Inhibitor, for Hyperuricemia Associated With Gout.
    Huneycutt E, Board C, Clements JN.
    J Pharm Pract; 2017 Jan 01; ():897190017734427. PubMed ID: 28980503
    [Abstract] [Full Text] [Related]

  • 8. Lesinurad, a Selective Uric Acid Reabsorption Inhibitor, in Combination With Febuxostat in Patients With Tophaceous Gout: Findings of a Phase III Clinical Trial.
    Dalbeth N, Jones G, Terkeltaub R, Khanna D, Kopicko J, Bhakta N, Adler S, Fung M, Storgard C, Baumgartner S, Perez-Ruiz F.
    Arthritis Rheumatol; 2017 Sep 01; 69(9):1903-1913. PubMed ID: 28597604
    [Abstract] [Full Text] [Related]

  • 9. Lesinurad for the treatment of hyperuricaemia in people with gout.
    Robinson PC, Dalbeth N.
    Expert Opin Pharmacother; 2017 Dec 01; 18(17):1875-1881. PubMed ID: 29103339
    [Abstract] [Full Text] [Related]

  • 10. The Effect of Lesinurad in Combination With Allopurinol on Serum Uric Acid Levels in Patients With Gout.
    Baumgartner S, Yeh LT, Shen Z, Kerr B, Manhard K, Quart B.
    J Clin Pharmacol; 2018 Sep 01; 58(9):1164-1170. PubMed ID: 29733441
    [Abstract] [Full Text] [Related]

  • 11. Novel uricosurics.
    Bardin T, Richette P.
    Rheumatology (Oxford); 2018 Jan 01; 57(suppl_1):i42-i46. PubMed ID: 29272511
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study.
    Dalbeth N, Jones G, Terkeltaub R, Khanna D, Fung M, Baumgartner S, Perez-Ruiz F.
    Arthritis Res Ther; 2019 Jan 07; 21(1):8. PubMed ID: 30616614
    [Abstract] [Full Text] [Related]

  • 13. Second-line treatment with lesinurad and allopurinol versus febuxostat for management of hyperuricemia: a cost-effectiveness analysis for Spanish patients.
    Presa M, Pérez-Ruiz F, Oyagüez I.
    Clin Rheumatol; 2019 Dec 07; 38(12):3521-3528. PubMed ID: 31420811
    [Abstract] [Full Text] [Related]

  • 14. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
    Kuriyama S.
    Clin Exp Nephrol; 2020 Mar 07; 24(Suppl 1):1-5. PubMed ID: 31754883
    [Abstract] [Full Text] [Related]

  • 15. Lesinurad: what the nephrologist should know.
    Sanchez-Niño MD, Zheng-Lin B, Valiño-Rivas L, Sanz AB, Ramos AM, Luño J, Goicoechea M, Ortiz A.
    Clin Kidney J; 2017 Oct 07; 10(5):679-687. PubMed ID: 28979780
    [Abstract] [Full Text] [Related]

  • 16. New urate-lowing therapies.
    Abhishek A.
    Curr Opin Rheumatol; 2018 Mar 07; 30(2):177-182. PubMed ID: 29251661
    [Abstract] [Full Text] [Related]

  • 17. Comparative efficacy and safety of lesinurad 200 mg and 400 mg combined with a xanthine oxidase inhibitor in hyperuricemic patients with gout: A Bayesian network meta-analysis of randomized controlled trials
.
    Song GG, Lee YH.
    Int J Clin Pharmacol Ther; 2019 Jul 07; 57(7):345-352. PubMed ID: 30990408
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia.
    Fleischmann R, Kerr B, Yeh LT, Suster M, Shen Z, Polvent E, Hingorani V, Quart B, Manhard K, Miner JN, Baumgartner S, RDEA594-111 Study Group.
    Rheumatology (Oxford); 2014 Dec 07; 53(12):2167-74. PubMed ID: 24509406
    [Abstract] [Full Text] [Related]

  • 19. Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
    Miner JN, Tan PK, Hyndman D, Liu S, Iverson C, Nanavati P, Hagerty DT, Manhard K, Shen Z, Girardet JL, Yeh LT, Terkeltaub R, Quart B.
    Arthritis Res Ther; 2016 Oct 03; 18(1):214. PubMed ID: 27716403
    [Abstract] [Full Text] [Related]

  • 20. Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy.
    Ruggeri M, Basile M, Drago C, Rolli FR, Cicchetti A.
    Pharmacoeconomics; 2018 May 03; 36(5):625-636. PubMed ID: 29557073
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.